Page 32 - Read Online

Page 634 Laubach et al. Cancer Drug Resist 2023;6:611-41 https://dx.doi.org/10.20517/cdr.2023.60

49. Campos-Contreras ADR, Díaz-Muñoz M, Vázquez-Cuevas FG. Purinergic signaling in the hallmarks of cancer. Cells 2020;9:1612.
DOI PubMed PMC
50. Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev
2017;276:121-44. DOI PubMed PMC
51. Ferretti E, Horenstein AL, Canzonetta C, Costa F, Morandi F. Canonical and non-canonical adenosinergic pathways. Immunol Lett
2019;205:25-30. DOI PubMed
52. Allard B, Allard D, Buisseret L, Stagg J. Publisher correction: the adenosine pathway in immuno-oncology. Nat Rev Clin Oncol
2020;17:650. DOI PubMed
53. Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth. Oncogene 2017;36:293-303. DOI PubMed
PMC
54. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo
imaging with plasma membrane luciferase. PLoS One 2008;3:e2599. DOI PubMed PMC
55. Mora-García ML, Ávila-Ibarra LR, García-Rocha R, et al. Cervical cancer cells suppress effector functions of cytotoxic T cells
through the adenosinergic pathway. Cell Immunol 2017;320:46-55. DOI
56. Sundström P, Stenstad H, Langenes V, et al. Regulatory T cells from colon cancer patients inhibit effector T-cell migration through
an adenosine-dependent mechanism. Cancer Immunol Res 2016;4:183-93. DOI PubMed
+
57. Shi L, Feng M, Du S, et al. Adenosine generated by regulatory T Cells induces CD8 T cell exhaustion in gastric cancer through
A2aR pathway. Biomed Res Int 2019;2019:4093214. DOI PubMed PMC
58. Maj T, Wang W, Crespo J, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade
resistance in tumor. Nat Immunol 2017;18:1332-41. DOI PubMed PMC
59. Giatromanolaki A, Kouroupi M, Pouliliou S, et al. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates
to hypoxia and immunosuppressive pathways. Life Sci 2020;259:118389. DOI
60. Vignali PDA, DePeaux K, Watson MJ, et al. Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit
antitumor immunity. Nat Immunol 2023;24:267-79. DOI PubMed PMC
+
61. Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M. The development and immunosuppressive functions of CD4
+ +
CD25 FoxP3 regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol 2012;3:190.
DOI PubMed PMC
62. Torres-Pineda DB, Mora-García ML, García-Rocha R, et al. Adenosine augments the production of IL-10 in cervical cancer cells
through interaction with the A adenosine receptor, resulting in protection against the activity of cytotoxic T cells. Cytokine
2B
2020;130:155082. DOI PubMed
63. King RJ, Shukla SK, He C, et al. CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer
pathogenesis. Oncogene 2022;41:971-82. DOI PubMed PMC
64. Ludwig N, Yerneni SS, Azambuja JH, et al. Tumor-derived exosomes promote angiogenesis via adenosine A receptor signaling.
2B
Angiogenesis 2020;23:599-610. DOI PubMed PMC
65. Ploeg EM, Ke X, Britsch I, et al. Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive
activity of carcinoma-derived extracellular vesicles. Cancer Lett 2021;521:109-18. DOI
66. Morandi F, Marimpietri D, Horenstein AL, Corrias MV, Malavasi F. Microvesicles expressing adenosinergic ectoenzymes and their
potential role in modulating bone marrow infiltration by neuroblastoma cells. Oncoimmunology 2019;8:e1574198. DOI PubMed
PMC
67. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through
adenosine production. J Immunol 2011;187:676-83. DOI PubMed
+
68. Chimote AA, Balajthy A, Arnold MJ, et al. A defect in KCa3.1 channel activity limits the ability of CD8 T cells from cancer patients
to infiltrate an adenosine-rich microenvironment. Sci Signal 2018;11:eaaq1616. DOI PubMed PMC
69. Chimote AA, Hajdu P, Kucher V, et al. Selective inhibition of KCa3.1 channels mediates adenosine regulation of the motility of
human T cells. J Immunol 2013;191:6273-80. DOI PubMed PMC
70. Feske S, Skolnik EY, Prakriya M. Ion channels and transporters in lymphocyte function and immunity. Nat Rev Immunol
2012;12:532-47. DOI PubMed PMC
+ 2+
71. Newton HS, Gawali VS, Chimote AA, et al. PD1 blockade enhances K channel activity, Ca signaling, and migratory ability in
cytotoxic T lymphocytes of patients with head and neck cancer. J Immunother Cancer 2020;8:e000844. DOI PubMed PMC
72. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates
immune suppression. J Exp Med 2007;204:1257-65. DOI PubMed PMC
73. Mandapathil M, Szczepanski MJ, Szajnik M, et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients
with head and neck cancer. Clin Cancer Res 2009;15:6348-57. DOI PubMed PMC
+
74. Koyas A, Tucer S, Kayhan M, Savas AC, Akdemir I, Cekic C. Interleukin-7 protects CD8 T cells from adenosine-mediated
immunosuppression. Sci Signal 2021;14:eabb1269. DOI PubMed
+
75. Cekic C, Linden J. Adenosine A receptors intrinsically regulate CD8 T cells in the tumor microenvironment. Cancer Res
2A
2014;74:7239-49. DOI PubMed PMC
76. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-
mediated inhibition of T-cell activation and expansion. Blood 1997;90:1600-10. DOI PubMed